Durvalumab
HRD
Institute of Cancer Research, United Kingdommonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the HRD cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib Institute of Cancer Research, United Kingdom | Phase 2 | CCC |
azd6738 Institute of Cancer Research, United Kingdom | Phase 2 | CCC |
hwh340 Hubei Biological Medicine Industrial Technology Institute Co., Ltd. | Phase 1 | CC |
Same molecule, other indications
Durvalumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →